The open secret of patent prosecution is that the office action is the process. Most applications that issue do so only after at least one rejection; first-action allowances are the rare exception. A rejection is the normal opening move of a game you are equipped to win. This checklist gives you a disciplined workflow for any office action. For the strategy in depth, pair it with responding to patent office actions: strategies for overcoming rejections; for the obviousness fight specifically, see the companion overcoming an obviousness rejection checklist.

Phase 1 — Read the action structurally and docket deadlines

  • Read the header: application number, examiner, art unit, and the statutory response period.
  • Look up the examiner's statistics (allowance rate, actions to disposition, interview frequency, PTAB reversal rate) via Patent Center/PEDS or a commercial analytics platform—they shape strategy.
  • Identify whether the action is non-final or final (this controls what you may do next).
  • Sort the body into rejections (patentability, appealable to PTAB), objections (formal defects, petitionable not appealable—37 C.F.R. § 1.181), and requirements (most importantly restriction).
  • Docket the deadline the moment the action arrives. The shortened statutory period is usually three months, extendable to six by fee (37 C.F.R. § 1.136(a)); the six-month outer limit is statutory and non-extendable (35 U.S.C. § 133).
  • Note that responding by the three-month date preserves patent term (PTA erodes after that), so treat three months as the real deadline.
  • Read the entire action, not just the rejections—objections and requirements bind too.

Phase 2 — Analyze each rejection

  • Build an element-by-element claim chart for each rejection, mapping claim limitations to the cited passages.
  • Read the cited references in full—the unquoted passages often hold the teaching-away or the missing element that wins.
  • Verify the examiner's claim construction first: during examination claims get their broadest reasonable interpretation in light of the specification (MPEP §§ 2111, 2111.01). Anchor terms in your own specification (you may be your own lexicographer). Claim construction is the lever beneath every other argument.

Phase 3 — Defeat § 102 anticipation

  • Confirm the examiner mapped a single reference to every limitation, arranged as in the claim (Verdegaal Bros., Inc. v. Union Oil Co., 814 F.2d 628 (Fed. Cir. 1987)).
  • Identify any genuinely missing limitation—if even one element is absent, the rejection fails as a matter of law (cite, don't wave).
  • Challenge improper inherency: a feature must be necessarily and inevitably present, not merely probable (In re Robertson, 169 F.3d 743 (Fed. Cir. 1999)); consider a short § 1.132 declaration.
  • Check the genus-species gap: a broad disclosure anticipates a species only if a skilled person would "at once envisage" it.
  • Confirm the reference is enabling and actually qualifies as prior art under the correct § 102 subsection.

Phase 4 — Defeat § 103 obviousness (the main event)

  • Attack the motivation to combine: a bare assertion that both references "relate to" the same field is a category, not a reason; the rejection needs "articulated reasoning with some rational underpinning" (In re NuVasive, Inc., 842 F.3d 1376 (Fed. Cir. 2016); KSR, 550 U.S. at 418).
  • Argue teaching away (In re Gurley, 27 F.3d 551 (Fed. Cir. 1994)) and change in principle of operation (In re Ratti, 270 F.2d 810 (C.C.P.A. 1959)).
  • Name impermissible hindsight where the examiner used your disclosure as a roadmap.
  • Build the affirmative Graham record: scope/content of the art, the precise difference, the level of skill, and objective indicia.
  • Marshal secondary considerations (commercial success, long-felt need, failure of others, unexpected results, copying, praise)—each with nexus to the claimed features, usually via declaration.

See overcoming an obviousness rejection checklist for the full obviousness workflow.

Phase 5 — Defeat § 101 eligibility (where applicable)

  • At Step 2A, reframe the claim as a technological improvement (Enfish, LLC v. Microsoft Corp., 822 F.3d 1327 (Fed. Cir. 2016); McRO, Inc. v. Bandai Namco, 837 F.3d 1299 (Fed. Cir. 2016)).
  • Police the level of abstraction—pull the claim down from "organizing human activity" to its specific technical limitations.
  • Argue the practical application prong from the USPTO's 2019 PEG (MPEP § 2106).
  • At Step 2B, demand Berkheimer evidence: an assertion that elements are well-understood, routine, and conventional needs one of four MPEP § 2106.05(d) categories of support; traverse any official notice to compel an affidavit (Berkheimer v. HP Inc., 881 F.3d 1360 (Fed. Cir. 2018)).
  • For AI/ML claims, map onto the USPTO's July 2024 guidance update (89 Fed. Reg. 58128) Examples 47–49.

See patent subject matter eligibility (Alice) checklist.

Phase 6 — Defeat § 112 rejections

  • For written description / enablement (§ 112(a)): point to specific passages as originally filed (no new matter), or narrow claims to the scope the disclosure teaches; enablement is measured against the full scope (Amgen Inc. v. Sanofi, 598 U.S. 594 (2023); In re Wands, 858 F.2d 731 (Fed. Cir. 1988)).
  • For definiteness (§ 112(b)): fix antecedent-basis problems, define relative terms in the specification, or show a settled meaning to a skilled person (Nautilus v. Biosig, 572 U.S. 898 (2014)).
  • For means-plus-function (§ 112(f)) terms, confirm the specification discloses corresponding structure.

Phase 7 — Handle restriction and preserve rejoinder

  • Confirm the examiner made both required showings: the inventions are independent/distinct and restriction imposes a serious burden (separate classification, status in the art, or field of search).
  • Traverse the serious-burden prong, not distinctness (arguing the inventions are not distinct can become a double-patenting/obviousness admission).
  • Make a provisional election with traverse (election without traverse forfeits the challenge).
  • Request rejoinder of non-elected claims if the elected claims are allowed (MPEP § 821.04).
  • Preserve non-elected subject matter in a divisional, which enjoys the § 121 safe harbor against double patenting.

Phase 8 — Choose your tools deliberately

  • Argue before you amend where a clean argument keeps full scope at no estoppel cost.
  • Amend purposefully: every narrowing amendment surrenders scope and triggers prosecution-history estoppel (Festo, 535 U.S. 722 (2002)); trace every added word to the original disclosure and use § 1.121 status identifiers.
  • Keep dependent claims laddering down as fallbacks; ensure the amended claim still reads on your actual or planned commercial embodiment.
  • Use declarations under 37 C.F.R. § 1.132 (inventor, expert, commercial) when argument alone cannot establish a needed fact.
  • Consider a Rule 1.130 declaration to remove a reference: § 1.130(a) attribution (the disclosure is the inventor's own work) or § 1.130(b) prior public disclosure (you disclosed first within the grace period)—watch the one-year wall and the § 102(a)(2) date problem.
  • Request an examiner interview (37 C.F.R. § 1.133)—the most underused tool; it correlates with higher allowance rates and lets you float an amendment before committing it. Note it does not toll your deadline.

Phase 9 — After a final rejection

  • Remember the response clock keeps running from the final action's mailing date.
  • After-final response (37 C.F.R. § 1.116): the examiner has discretion to enter it; note AFCP 2.0 ended December 14, 2024, so lean on earlier interviews and tighter pre-final amendments. Use the two-month rule (MPEP § 706.07(f)) to reduce extension fees.
  • RCE (37 C.F.R. § 1.114) reopens prosecution—but fees rose effective Jan. 19, 2025 (~$1,500 first; ~$2,860 second+ for large entities); an RCE filed mid-appeal withdraws the appeal.
  • Continuation (35 U.S.C. § 120) preserves priority while pursuing different claims—file on or before the day you pay the issue fee (copendency is unforgiving); note long-pendency surcharges (~$2,700 at 6+ years, ~$4,000 at 9+).
  • Appeal to the PTAB when the examiner committed legal error further argument will not cure.

Phase 10 — Appeal to the PTAB (if chosen)

  • Confirm the right exists (claim twice rejected; 35 U.S.C. § 134(a)).
  • File the Notice of Appeal with fee by the response due date; consider a Pre-Appeal Brief Request for Review for a clear error.
  • File the Appeal Brief (37 C.F.R. § 41.37) addressing every ground (unargued grounds are waived); structure by ground, lead with your strongest argument.
  • Track the Examiner's Answer, Reply Brief, forwarding fee, and oral-hearing request and their deadlines.
  • Stop amending once you appeal—you are now litigating the record you have.

Phase 11 — Final review and file

  • Address every rejection and objection—silence concedes.
  • Argue the claims, not the specification's marketing prose.
  • Characterize the prior art accurately (quote it)—mischaracterization destroys credibility.
  • Confirm every amendment is supported and new-matter-free and no argument contradicts an earlier one.
  • File before the deadline with correct fees; if tight, pay the extension fee and use a certificate of transmission on a last-day filing.

Common mistakes

  • Missing the deadline (no brilliance survives an untimely filing).
  • Failing to address every rejection (an unargued ground is waived on appeal).
  • Arguing the specification instead of the claims.
  • Amending when you could have argued (needless Festo estoppel).
  • Traversing restriction on the wrong ground (admit-nothing on distinctness; fight serious burden).

Primary authority

  • 35 U.S.C. §§ 101, 102, 103, 112, 120, 121, 132–134. 37 C.F.R. §§ 1.111, 1.116, 1.121, 1.130, 1.132, 1.133, 1.136, 41.37.
  • KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007); Graham v. John Deere Co., 383 U.S. 1 (1966); In re NuVasive, Inc., 842 F.3d 1376 (Fed. Cir. 2016); Alice Corp. v. CLS Bank Int'l, 573 U.S. 208 (2014); Berkheimer v. HP Inc., 881 F.3d 1360 (Fed. Cir. 2018); Amgen v. Sanofi, 598 U.S. 594 (2023); Nautilus v. Biosig, 572 U.S. 898 (2014); Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 U.S. 722 (2002).
  • USPTO MPEP §§ 706, 713 (interviews), 714.13, 821.04 (rejoinder), 2106 (eligibility), 2143 (obviousness rationales). USPTO Patent Center: https://patentcenter.uspto.gov

This checklist is general information, not legal advice. Confirm current USPTO fees and rules and consult a registered patent practitioner.

Related resources